Express Scripts to cover Repatha and Praluent

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.

from Most popular articles from Medical Marketing and Media http://ift.tt/1LhNiFh